beta
Trial Radar AI
Clinical Trial NCT05460780 (TIDE) for Breast Cancer Female, Breast Cancer Prevent, Breast Reconstruction is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View

First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer (TIDE)

Recruiting
Clinical Trial NCT05460780 (TIDE) is an interventional study for Breast Cancer Female, Breast Cancer Prevent, Breast Reconstruction that is recruiting. It started on 1 July 2022 with plans to enroll 50 participants. Led by Quanta Medical, it is expected to complete by 31 December 2028. The latest data from ClinicalTrials.gov was last updated on 20 March 2025.
Brief Summary
This study is a first in human, two-stage single arm non-comparative study of safety and performance.

The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.

Official Title

First-in-human Study of MATTISSE® Tissue Engineering Chamber in Adult Female After Total Mastectomy for Breast Cancer in Immediate or Delayed 2-stage Tissue Expander Reconstruction or Conversion from Implant-based to Autologous Reconstruction

Conditions
Breast Cancer FemaleBreast Cancer PreventBreast Reconstruction
Publications
Scientific articles and research papers published about this clinical trial:
Show More
Other Study IDs
  • TIDE
  • 3121_MATFIH22
NCT ID Number
Start Date (Actual)
2022-07-01
Last Update Posted
2025-03-20
Completion Date (Estimated)
2028-12-31
Enrollment (Estimated)
50
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Primary Purpose
Other
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalMATTISSE TEC
Patient included receive MATTISSE TEC
MATTISSE TEC
Tissue engineering chamber MATTISSE
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Safety objective: To assess the 6 months surgical complications rate of MATTISSE® TEC implant-based immediate breast reconstruction. Adverse events will be recorded.
Minor complications include: * Superficial skin necrosis that requires only debridement * Flap necrosis * Subcutaneous hematoma: any hematoma requiring surgical exploration * Inflammatory reaction * Seroma: defined as that which requires echo-guided puncture at least once after drain removal. * Pain * Delayed wound healing/wound dehiscence: any wound healing problems, detected during clinical examination and not requiring an intervention * Implant malposition * Superficial Venous Thrombosis (Mondor disease) * Capsular contracture Major complications include: * All complications that lead to MATTISSE® TEC removal: * Skin necrosis leading to implant exposure * Infection * Implant malposition leading to implant exposure * Device failure or defect: when the implant breaks or collapses, e.g., the base separates from the shell, failure at the time of surgical placement (fracture of the TEC before placement) * Granuloma.
6 months post-surgery
Performance objective: To assess the efficacy at 6 months post-operation of breast reconstruction using MATTISSE® breast implants in patients undergoing breast reconstitution after total mastectomy surgery for cancer.
Success is defined as: * Tissue expansion (flap enlargement) from implantation up to 6 months post operation --\> A 50% increase in the expanded size at 6 months compared to initial size flap is considered as a success. Indeed, the optimal growth of the flap is expected at 6 months, * Tissue expansion will be assessed using MRI at discharge (after surgery) and 6 months post operative. The volume of flap at 6 months will be compared to the flap size initially implanted. All MRI imaging will be assessed by and independent expert radiologist. Failure is defined as: * less than 50% increase in the expanded size at 6 months compared to initial size flap MATTISSE® Prothesis removal
6 months post-surgery
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Evolution of tissue expansion (flap enlargement) from implantation up to 36 months post operation.
Tissue expansion will be assessed using MRI at discharge (after surgery), 12, 24 and 36 months post operative. All MRI imaging will be assessed by and independent expert radiologist.
Surgery visit, 3, 6, 12, 24 and 36 months post-intervention
Evolution of breast softness from inclusion to 36 months
* The breast softness will be assessed by investigator surgeon and patients themselves at discharge (after surgery), 3, 6 ,12, 24 and 36 months as: * Stage 1: Breast is soft * Stage 2: Breast is hard * Stage 3: Breast is hard with distortion * Stage 4: Breast is hard, painful with distortion
Surgery visit, 3, 6, 12, 24 and 36 months post-intervention
Evolution of MATTISSE® TEC resorption until 36 months follow up: the resorption is active between 6 and 12 months after surgery.
MATTISSE® TEC resorption will be observed quantitatively on MRI achieved at 3, 6, 12, 24 and 36 months associated with the touch of the surgeon and patients feeling. The TEC resorption will be classified as: * Absent: no resorption at all. * Small resorption: TEC has been reabsorbed a little bit compared to the initial * Great resorption: TEC has been absorbed a lot but not totally * Total: Shell and base are no longer visible on the MRI and not felt by the surgeon
Surgery visit, 3, 6, 12, 24 and 36 months post-intervention
The volume of the reconstructed breast compared to the volume of the contralateral one at 12, 24 and 36 months
At 12, 24 and 36 months, we will assess during physical examinations, the volume of the reconstructed breast and the volume of the contralateral one.
3, 6, 12, 24 and 36 months post surgery
Aesthetic breast appearance before and after surgery using photo
Aesthetic breast appearance will be assessed before surgery, 6 at 12, 24 and 36 months post-surgery using standardized photographs. The assessment will be done by the surgeon and 2 independent external specialists who validated standardized photographs. The following scoring points will be used: * Excellent: Treated breast nearly identical to that before surgery * Good: Treated breast slightly different to that before surgery * Fair: Treated breast clearly different to that before surgery but not seriously distorted * Poor: Treated breast seriously distorted compared to that before surgery
3, 6, 12, 24 and 36 months post surgery
The maintain of breast (i.e., flap) volume stability at 12, 24 and 36 months compared to that at 6 months
Flap volume at 12, 24 and 36 months is compared at that assessed at 6 months using MRI. All MRI imaging will be assessed by and independent expert radiologist.
3, 6, 12, 24 and 36 months post surgery
The impact of the flap transfer on the donor site assessed at surgery, 3, 6, 12, 24 and 36months post-surgery
Impact of the flap transfer on the donor site will be assessed at surgery, 3, 6, 12, 24 and 36 months post-surgery using different parameters: * Tissue necrosis (Yes/ No) * Symmetry of the donor site area (comparing to the other side of the patient): Yes/ No
3, 6, 12, 24 and 36 months post surgery
Pain (VAS)
Pain score will be assessed at inclusion, discharge, 3, 6, 12, 24 and 36 month using a 10 Visual Analogue Scale \[VAS, 0 (no pain) and 10 (worst possible pain)\]
3, 6, 12, 24 and 36 months post surgery
The quality of life and the satisfaction of patients
Quality of life and patients' satisfaction will be done through the BREAST-Q© questionnaire (module of reconstruction pre and post-surgery version) at inclusion and at 3, 6 and 12 months post operative. The quality of life is evaluated through 2 scales (psychological well-being and physical well-being: breast). The satisfaction is evaluated with 1 scale : (satisfaction with breast).
3, 6, 12, 24 and 36 months post surgery
Surgeon satisfaction regarding the use of MATTISSE® TEC and implantation procedure.
\- Surgeons' satisfaction regarding the use of MATTISSE® TEC and implantation procedure will be assessed on: Global satisfaction of the surgeon (5 points Likert scale) * Ease of use * Material ergonomics * Ease of insertion * Ease of fixing
Visit 2, surgery
Evolution of biological parameters up to 6 months after surgery
Complete blood counts evolution will be assessed at inclusion, at discharge, and at 3 and 6 months post-implantation, by measuring Hemoglobin , leukocytes Lymphocyte rate Neutrophil rate and Thrombocytes Units: * Hemoglobin : g/L * leukocytes :10⁹/L * Lymphocyte rate : % * Neutrophil rate : % * Thrombocytes : 10⁹/L
Inclusion, Discharge, 3, 6 months post-intervention
Evolution of biological parameters up to 6 months after surgery
C-reactive protein evolution will be assessed at inclusion, at discharge, and at 3 and 6 months post-implantation, by measuring CRP Unit: \- CRP : nmoL/L
Inclusion, Discharge, 3, 6 months post-intervention
Evolution of biological parameters up to 6 months after surgery
Total protein evolution will be assessed at inclusion, at discharge, and at 3 and 6 months post-implantation, by total protein assay Unit: Total protein: Normal or Not normal
Inclusion, Discharge, 3, 6 months post-intervention
Evolution of biological parameters up to 6 months after surgery
Protein electrophoresis will be assessed at inclusion, at discharge, and at 3 and 6 months post-implantation, by performing protein electrophoresis. Unit : Protein electrophoresis: Normal or Not normal
Inclusion, Discharge, 3, 6 months post-intervention
Safety up to 36 months post operation
Safety up to 36 months, will be assessed by measuring the complication rate after breast reconstruction using MATTISSE® TEC. Adverse events up to 36 months post operation will be recorded.
Surgery visit, 3, 6, 12, 24 and 36 months post-intervention
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female

Criteria related to pathology:

  • Female patient over 18 Years old

  • Patient who required autologous breast reconstruction:

    • Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer
    • Breast reconstruction after unilateral preventive total mastectomy
    • or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation
    • or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it.
  • For patient with active cancer: Patient with early-stage cancer (stage 0, I or II, with tumor size < 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site

  • Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction.

  • Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting.

  • Patient medically fit for surgery without significant comorbidities

  • Breast cup-size less than D

  • Body mass index >20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment

  • Adequate hematopoietic functions

Criteria related to population:

  • Subjects who have given free, informed and written consent to participate in the study;
  • Patient able to answer questionnaires, able to communicate in the language of the study country;
  • Subjects affiliated to a social security schema or entitled to a social security scheme.

Non-inclusion Criteria:

Pathology related criteria:

  • Patient undergoing bilateral reconstruction
  • Patient undergoing bilateral preventive mastectomy
  • Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation
  • Previous history of radiotherapy on the breast area or on the flap donor site
  • Previous history of breast or axillary surgery that does not allow fat flap dissection
  • Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI
  • Body mass index >30 kg/m2
  • Taking medication for weight loss at the time of inclusion visit
  • Presence of major medical conditions that may compromise patient's health and healing
  • Diabetes and a history of gestational diabetes
  • Active smoking
  • Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease)
  • Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination
  • Allergy to anesthetics or contrast media
  • Immunocompromised patient (HIV) or patient used immunosuppressants

Population related criteria

  • Pregnant patient
  • or breastfeeding patient or woman who has nursed a child three months within inclusion
  • Participation in a clinical trial in the 3 months prior to the initial visit
  • Predicted unavailability during study.
  • Patient deprived of liberty or under guardianship.
  • Patient unable to give consent

Medical device related criteria

  • Allergy to any of the components of the medical device.

  • Positive or suspicious extemporaneous sentinel node biopsy
  • Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler
  • Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment
Quanta Medical logoQuanta Medical
Lattice Medical logoLattice Medical
Study Central Contact
Contact: Pierre GUERRESCHI, Pr, 03.20.44.56.59, [email protected]
3 Study Locations in 2 Countries

France

CHU de Strasbourg, Strasbourg, France, 67091, France
Frédéric BODIN, Pr, Contact
Recruiting

Nord

Hospital of Lille, Lille, Nord, 59000, France
Pierre Guerreschi, Prof., Contact
Recruiting
Institute of Clinical Oncology, Tbilisi, 0159, Georgia
Gia NEMSADZE, Pr, Contact
Recruiting